Bronchitol Gets Narrow Approval Vote From Advisory Cmte., Leaving US FDA Host Of Issues To Consider

 
• By Michael Cipriano

Pulmonary-Allergy Drugs Advisory Committee votes 9-7 that the benefits of Pharmaxis' cystic fibrosis drug outweigh its risks, leaving the FDA with a muddled verdict.  

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers